Roger B. Cohen, MD

Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Penn Medicine Provider

About me

  • Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

My education and training

  • Medical School: Harvard Medical School
  • Residency: Mount Sinai Medical Center
  • Fellowship: Mount Sinai Medical Center
  • Fellowship: National Cancer Institute

Reviews

Average Rating

726 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
April 2026
doctor cohen sincerely cares about the wellbeing of his patients.
Anonymous
April 2026
exceptional care. all of our questions were. answered and we left more confident about the path forward.
Anonymous
April 2026
very efficient
Anonymous
April 2026
a long relationship between dr. cohen and i is very positive point.

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Cohen is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Bleiberg BA, Reed-Guy L, Cohen RB, Aggarwal C, Langer CJ, Singh AP, Marmarelis ME. Carboplatin plus pemetrexed versus pemetrexed alone in advanced thymoma and thymic carcinoma: a retrospective cohort study , Front Oncol, 16: 2026,1795920


Lukens JN, Riina MD, Weinstein G, MacDuffie E, Ramkissoon A, Baron J, Berger M, Messing I, Gentile M, Maxwell R, Ojerholm E, Swisher-McClure S, Santos AG, Porier K, Basu D, Brody R, Cannady S, Carey R, Chalian A, Newman J, Rajasekaran K, Rassekh C, Shanti R, Cohen RB, Singh A, Sun L, Montone K, Lin A. Long-Term Results of a Phase 2 Clinical Trial of Radiation Volume and Dose Deintensification Following Transoral Robotic Surgery and Neck Dissection for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma , Int J Radiat Oncol Biol Phys: 2026


Bleiberg BA, Scholes DG, Reed-Guy L, Dravid D, Sun LL, Singh AP, Cohen RB, Langer CJ, Marmarelis ME, Aggarwal C. The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing , J Liq Biopsy, 12: 2026,100461


Qu K, Stalker M, Hwang WT, Cohen RB, Sun L. Recurrent/metastatic relapse after definitive treatment for HNSCC: timing, patterns, and survival , Front Oncol, 16: 2026,1738860


Barsouk A, Heidlauf A, Goel K, Rushkin L, Anran Huang A, Elghawy O, Yu C, Wang L, Yang D, Kurian M, Reed-Guy L, Sun L, Singh A, Aggarwal C, Cohen RB, Langer C, Marmarelis ME. Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) , Lung Cancer, 213: 2026,108936


Friedes C, Iocolano M, Yegya-Raman N, Kucharczuk JC, Pechet TTV, Cohen RB, Aggarwal C, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, D'Avella C, Singh AP, Davis CW, Langer CJ, Bradley J, Feigenberg SJ. Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy , Am J Clin Oncol, 49: 2025,212-218


Yegya-Raman N, Ko K, Han IS, Mitchell JD, Zou W, Ohri N, Jabbour SK, Mak RH, Robinson C, Levin WP, Barrett L, Xia C, Berlin E, Bravo P, Carli MD, Cohen R, Hutton S, Keltz J, Wang J, Fasan O, Nagda SN, Seo A, Smith AM, Sun L, Soike M, Kole AJ, Walls G, Feigenberg SJ, Ky B. Cardiac substructure radiotherapy dose and changes in physical activity and quality of life after chemoradiotherapy for NSCLC: a secondary analysis of the CLARITY prospective study , Clin Transl Radiat Oncol, 56: 2025,101070


Gobillot TA, Weinstein G, Cao A, Lee JJ, Brody RM, Basu D, O'Malley BW Jr, Farwell DG, Cannady S, Lin A, Lukens J, Gentile M, Newman JG, Chalian AA, Sun L, Lakshmipathy D, Cohen RB, Rasskeh CH, Rajasekaran K. Outcomes of HPV+ Oropharyngeal Carcinoma of Unknown Primary Following Transoral Robotic Surgery , Laryngoscope: 2025


Theodore A Gobillot, Gregory Weinstein, Austin Cao, Jake J Lee, Robert M Brody, Devraj Basu, Bert W O'Malley Jr, D Gregory Farwell, Steven Cannady, Alexander Lin, John Lukens, Michelle Gentile, Jason G Newman, Ara A Chalian, Lova Sun, Deepak Lakshmipathy, Roger B Cohen, Christopher H Rasskeh, Karthik Rajasekaran Outcomes of HPV+ Oropharyngeal Carcinoma of Unknown Primary Following Transoral Robotic Surgery , The Laryngoscope: 2025


Cohen RB, Jimeno A, Hreno J, Sun L, Wallén-Öhman M, Millrud CR, Sanfridson A, Garcia-Ribas I. Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors , Invest New Drugs: 2025